Thymosin Alpha 1-RGDR (Tα1-RGDR)
Tα1-RGDR combines the immunomodulatory properties of Thymosin Alpha 1 with tumor-targeting RGDR sequence through a flexible GGGG linker. This 36-amino acid modified peptide binds selectively to integrin αvβ3 and Neuropilin-1 (NRP-1) receptors overexpressed on tumor cells and vascular endothelium.
The RGDR motif contains both the RGD integrin-binding sequence and a C-terminal R/KXXR/K motif for NRP-1 recognition. Research in mouse models shows Tα1-RGDR targets tumor tissue more efficiently than unmodified Tα1 while maintaining immune system activation through CD4+ and CD8+ T cell upregulation.
Studies demonstrate applications in non-small cell lung cancer, melanoma, and other solid tumor models where integrin αvβ3 expression is elevated.
For in vitro research applications only.
